Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysis.

ABSTRACT:

Background

The emergence of novel human epidermal growth factor receptor 2 (HER2)-targeting drugs has provided a new therapeutic option for HER2-low triple-negative breast cancer (TNBC) patients who had limited treatment choices previously. However, the biological implications and prognostic significance of HER2-low status in TNBC are still not fully appreciated.

Methods

Utilizing a single-center multi-omics cohort of TNBC patients that includes whole exome sequencing and RNA sequencing data, this study aims to explore the clinical and molecular characteristics between HER2-low and HER2-0 TNBC.

Results

The study comprised 207 patients with HER2-low TNBC and 153 patients with HER2-0 TNBC. Findings revealed that HER2-low tumors exhibited lower tumor grade, more nodal in

SUBMITTER: Yang Y 

PROVIDER: S-EPMC12495238 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature